Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 902 Thousand EUR | 314.9% |
| 2022 | 255 Thousand EUR | -90.31% |
| 2021 | 2.63 Million EUR | -27.65% |
| 2020 | 3.63 Million EUR | -16.62% |
| 2019 | 4.36 Million EUR | 165.07% |
| 2018 | 1.64 Million EUR | 13.99% |
| 2017 | 1.44 Million EUR | -2.3% |
| 2016 | 1.47 Million EUR | 118.96% |
| 2015 | 675 Thousand EUR | 63.44% |
| 2014 | 413 Thousand EUR | 288.27% |
| 2013 | 106.37 Thousand EUR | -88.46% |
| 2012 | 921.38 Thousand EUR | 692.54% |
| 2011 | 116.25 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 155 Thousand EUR | 0.0% |
| 2023 FY | 17.68 Million EUR | 6836.86% |
| 2023 Q4 | 902 Thousand EUR | 0.0% |
| 2023 Q2 | 536 Thousand EUR | 0.0% |
| 2022 Q1 | 2.39 Million EUR | -8.97% |
| 2022 Q4 | 16.88 Million EUR | 0.0% |
| 2022 FY | 255 Thousand EUR | -90.31% |
| 2022 Q2 | 2.16 Million EUR | -9.68% |
| 2021 Q4 | 2.63 Million EUR | -8.2% |
| 2021 Q2 | 3.08 Million EUR | -9.36% |
| 2021 Q1 | 3.39 Million EUR | -6.57% |
| 2021 FY | 2.63 Million EUR | -27.65% |
| 2021 Q3 | 2.86 Million EUR | -6.95% |
| 2020 Q4 | 3.63 Million EUR | 0.0% |
| 2020 Q2 | 3.7 Million EUR | 0.0% |
| 2020 FY | 3.63 Million EUR | -16.62% |
| 2019 Q4 | 4.36 Million EUR | 0.0% |
| 2019 Q2 | 4.93 Million EUR | 0.0% |
| 2019 FY | 4.36 Million EUR | 165.07% |
| 2018 Q4 | 1.64 Million EUR | 0.0% |
| 2018 FY | 1.64 Million EUR | 13.99% |
| 2018 Q2 | 1.29 Million EUR | 0.0% |
| 2017 FY | 1.44 Million EUR | -2.3% |
| 2017 Q2 | 1.19 Million EUR | 0.0% |
| 2017 Q4 | 1.44 Million EUR | 0.0% |
| 2016 FY | 1.47 Million EUR | 118.96% |
| 2016 Q4 | 1.47 Million EUR | 0.0% |
| 2016 Q2 | 1.74 Million EUR | 0.0% |
| 2015 FY | 675 Thousand EUR | 63.44% |
| 2015 Q2 | 502 Thousand EUR | 0.0% |
| 2015 Q4 | 675 Thousand EUR | 0.0% |
| 2014 FY | 413 Thousand EUR | 288.27% |
| 2014 Q2 | 317.8 Thousand EUR | 0.0% |
| 2014 Q4 | 413 Thousand EUR | 0.0% |
| 2013 Q4 | 106.37 Thousand EUR | 0.0% |
| 2013 Q2 | 167.18 Thousand EUR | 0.0% |
| 2013 FY | 106.37 Thousand EUR | -88.46% |
| 2012 Q4 | 921.38 Thousand EUR | 0.0% |
| 2012 FY | 921.38 Thousand EUR | 692.54% |
| 2011 FY | 116.25 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 73.392% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 98.374% |
| Adocia SA | 13.08 Million EUR | 93.108% |
| Aelis Farma SA | 4.03 Million EUR | 77.662% |
| Biophytis S.A. | 8.27 Million EUR | 89.093% |
| Advicenne S.A. | 17.42 Million EUR | 94.824% |
| genOway Société anonyme | 7.23 Million EUR | 87.53% |
| IntegraGen SA | 1.12 Million EUR | 19.803% |
| Medesis Pharma S.A. | 1.2 Million EUR | 24.833% |
| Neovacs S.A. | 650 Thousand EUR | -38.769% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1350.767% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 79.295% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 66.8% |
| Sensorion SA | 2.86 Million EUR | 68.558% |
| Theranexus Société Anonyme | 3.64 Million EUR | 75.24% |
| TME Pharma N.V. | 1.16 Million EUR | 22.642% |
| Valbiotis SA | 6.87 Million EUR | 86.886% |
| TheraVet SA | 1.15 Million EUR | 22.232% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 89.976% |
| argenx SE | 18.1 Million EUR | 95.018% |
| BioSenic S.A. | 28.16 Million EUR | 96.797% |
| DBV Technologies S.A. | 13.01 Million USD | 93.071% |
| Galapagos NV | 9.59 Million EUR | 90.6% |
| Genfit S.A. | 70.17 Million EUR | 98.715% |
| GeNeuro SA | 7.73 Million EUR | 88.343% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 82.962% |
| Innate Pharma S.A. | 39.89 Million EUR | 97.739% |
| Inventiva S.A. | 37.4 Million EUR | 97.589% |
| MaaT Pharma SA | 14.07 Million EUR | 93.591% |
| MedinCell S.A. | 58.96 Million EUR | 98.47% |
| Nanobiotix S.A. | 50.56 Million EUR | 98.216% |
| Onward Medical N.V. | 16.87 Million EUR | 94.654% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 93.41% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 98.031% |
| Oxurion NV | 12.33 Million EUR | 92.687% |
| Pharming Group N.V. | 155.29 Million EUR | 99.419% |
| Poxel S.A. | 46.9 Million EUR | 98.077% |
| GenSight Biologics S.A. | 18.42 Million EUR | 95.105% |
| Transgene SA | 1.25 Million EUR | 28.242% |
| Financière de Tubize SA | 79.2 Million EUR | 98.861% |
| UCB SA | 3.03 Billion EUR | 99.97% |
| Valneva SE | 208.81 Million EUR | 99.568% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -2273.684% |